Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hyperinsulinism-hyperammonemia syndrome (HIHA) is a frequent form of diazoxide-sensitive diffuse hyperinsulinism, characterized by an excessive/ uncontrolled insulin secretion (inappropriate for the level of glycemia), asymptomatic hyperammonemia and recurrent episodes of profound hypoglycemia induced by fasting and protein rich meals, requiring rapid and intensive treatment to prevent neurological sequelae. Epilepsy and cognitive deficit that are unrelated to hypoglycemia may also occur.
Data assembled from 8 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Features include very common findings: Asymptomatic hyperammonemia, Failure to thrive, and Reactive hypoglycemia; and common findings: Hyperinsulinemic hypoglycemia, Global developmental delay, Specific learning disability, and Generalized non-motor (absence) seizure and others. 17 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Hypoglycemic seizures, Intellectual disability, Global developmental delay |
Growth and development | 1 | Failure to thrive |
Digestive system | 1 | Abnormality of the pancreatic islet cells |
Lab test results | 1 | Increased urine alpha-ketoglutarate concentration |
GLUD1 encodes glutamate dehydrogenase 1 (558 aa). Mitochondrial glutamate dehydrogenase that catalyzes the conversion of L-glutamate into alpha-ketoglutarate. Highest expression in Liver (306.2 TPM) and Brain Nucleus accumbens basal ganglia (296.5 TPM).
Hyperinsulinism-hyperammonemia syndrome is caused by mutations in the GLUD1 gene on chromosome 10.
The GLUD1 protein participates in alpha-ketoglutarate + NH4+ + NAD(P)H + H+ glutamate + NAD(P)+ (GLUD1,2), glutamate + NAD(P)+ = alpha-ketoglutarate + NH4+ + NAD(P)H + H+ (GLUD1,2), and Transcriptional Regulation by MECP2 pathways.
GLUD1 is classified as a druggable target (Enzyme category) with score 52.2.
Genetic testing for GLUD1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 3 very common features, 10 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
11 publications have been identified in PubMed for hyperinsulinism-hyperammonemia syndrome. Research spans Case Report / Case Series (36%), Review / Meta-Analysis (27%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 4 | 36% |
Research summaries | 3 | 27% |
Laboratory research | 2 | 18% |
Disease patterns and progression | 2 | 18% |
Bennett JJ (2026). [PMID: 42184599](https://pubmed.ncbi.nlm.nih.gov/42184599/). *EBioMedicine*. [Basic Science / Preclinical]
Rosenfeld E (2026). [PMID: 41980002](https://pubmed.ncbi.nlm.nih.gov/41980002/). *Horm Res Paediatr*. [Review / Meta-Analysis]
Wong T (2026). [PMID: 41982675](https://pubmed.ncbi.nlm.nih.gov/41982675/). *Front Pharmacol*. [Review / Meta-Analysis]
Velde CD (2025). [PMID: 38963811](https://pubmed.ncbi.nlm.nih.gov/38963811/). *The Journal of clinical endocrinology and metabolism*. [Epidemiology / Natural History]
Yavas Abali Z (2025). [PMID: 40382736](https://pubmed.ncbi.nlm.nih.gov/40382736/). *Endocrine*. [Case Report / Case Series]
Zeng Z (2025). [PMID: 40573270](https://pubmed.ncbi.nlm.nih.gov/40573270/). *Pharmaceuticals (Basel, Switzerland)*. [Basic Science / Preclinical]
Abdulghfar MM (2025). [PMID: 40652260](https://pubmed.ncbi.nlm.nih.gov/40652260/). *Journal of medical case reports*. [Case Report / Case Series]
Sherin S (2024). [PMID: 39759686](https://pubmed.ncbi.nlm.nih.gov/39759686/). *Cureus*. [Case Report / Case Series]
Cheng M (2024). [PMID: 40302972](https://pubmed.ncbi.nlm.nih.gov/40302972/). *Pediatric diabetes*. [Epidemiology / Natural History]
Aleshina YA (2024). [PMID: 38673928](https://pubmed.ncbi.nlm.nih.gov/38673928/). *International journal of molecular sciences*. [Review / Meta-Analysis]